Free tool
FAERS Monitor: Santyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 101995 or its brand name (Santyl, Collagenase). Reports on generic versions are filed under their own applications.
Reports
1,690
Serious
1,022
60% of reports
Hospitalization
400
Death reported
486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death388
- wound complication159
- drug ineffective120
- application site pain109
- off label use68
- pain64
- impaired healing61
- wound59
- acute kidney injury52
- chronic kidney disease52
- nausea48
- diarrhoea46
- wound infection46
- renal failure44
- wound secretion44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 21 |
| 2014 | 14 |
| 2015 | 50 |
| 2016 | 115 |
| 2017 | 136 |
| 2018 | 171 |
| 2019 | 163 |
| 2020 | 91 |
| 2021 | 77 |
| 2022 | 147 |
| 2023 | 112 |
| 2024 | 139 |
| 2025 | 227 |
| 2026 | 225 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,469 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wound complicationSignal | 159 | 604.6 | 519.4 | 90,819 |
| wound secretionSignal | 44 | 141.4 | 105.5 | 5,929 |
| application site painSignal | 109 | 61.9 | 51.6 | 6,443 |
| wound infectionSignal | 46 | 52.5 | 39.5 | 2,264 |
| woundSignal | 59 | 26.3 | 20.5 | 1,411 |
| impaired healingSignal | 61 | 23.2 | 18.1 | 1,271 |
| chronic kidney diseaseSignal | 52 | 8.5 | 6.5 | 339 |
| deathSignal | 388 | 5.6 | 5.1 | 1,526 |
| acute kidney injurySignal | 52 | 4.2 | 3.2 | 126 |
| renal failureSignal | 44 | 4.1 | 3.1 | 102 |
| pain | 64 | 1.3 | 1.0 | 4 |
| drug ineffective | 120 | 1.1 | 1.0 | 2 |
| off label use | 68 | 1.0 | 0.8 | 0 |
| diarrhoea | 46 | 0.9 | 0.7 | 1 |
| nausea | 48 | 0.8 | 0.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.